Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2023-05-11 Regulatory Filings
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
Regulatory Filings Classification · 1% confidence The document is a news release dated May 11, 2023, announcing that MorphoSys AG will present data on its oncology pipeline (pelabresib, tafasitamab, tulmimetostat) at upcoming medical conferences (ASCO and EHA). It details the abstracts and presentation schedules. This is not a formal regulatory filing like a 10-K or IR, nor is it a transcript (CT) or a formal earnings release (ER). It is an announcement about scientific data presentation, which falls under general investor/corporate news. Since it is a news announcement detailing upcoming scientific data presentations and corporate updates, and does not fit the specific categories like ER, CT, or IP (which is usually a presentation deck), the most appropriate general category for this type of corporate news release, especially one detailing scientific progress and upcoming conference presentations, is Regulatory Filings (RNS) as a catch-all for non-standard announcements, or potentially Investor Presentation (IP) if it were the presentation itself. Given the format is a press release announcing future data presentations, RNS is the best fit as a general corporate news announcement that doesn't map perfectly to the other specific financial/regulatory documents.
2023-05-11 English
Declaration of Voting Results & Voting Rights Announcements 2023
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed sections regarding the 'Notification of Major Holdings' under German Securities Trading Act (WpHG) regulations. It specifies the acquisition/disposal of shares with voting rights, the date the threshold was crossed (09 May 2023), and the resulting percentage change (from 3.21% to 5.01%) for the shareholder 'Adage Capital Partners, L.P.' and related entities. This content directly corresponds to the definition of reporting changes in significant share ownership levels, which maps to the Major Shareholding Notification code (MRQ). Although the header mentions 'Voting Rights Announcements', the core content is a major holding disclosure, which is best classified as MRQ.
2023-05-11 English
MorphoSys AG: Charlotte Lohmann, Allocation of 157 shares as part of her remuneration as member of the Managing Board (Performance Share Plan 2019) (issuer's own shares)
Director's Dealing Classification · 1% confidence The document is explicitly titled 'Directors’ Dealings' and details a transaction involving a member of the Managing Board (Charlotte Lohmann) regarding the allocation of shares as part of her remuneration. This directly matches the definition for Director's Dealing (insider trades by executives). The corresponding code is DIRS.
2023-05-05 English
Q1 statement / Q1 financial report 2023
Interim / Quarterly Report Classification · 1% confidence The document is titled 'First Quarter Interim Statement January – March 2023' and contains detailed financial results, including a Consolidated Statement of Profit or Loss, Balance Sheet, and Cash Flows for the period. It provides a comprehensive analysis of the company's operating performance, R&D, and financial guidance. It is clearly a quarterly financial report, not an announcement or a summary, and fits the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-04 English
MorphoSys AG Reports First Quarter 2023 Financial Results
Earnings Release Classification · 1% confidence The document is explicitly titled "MorphoSys AG Reports First Quarter 2023 Financial Results" and contains detailed financial tables, key performance indicators (KPIs) for the quarter (Q1 2023), operating expenses, net loss figures, and a full-year financial guidance section. The presence of detailed financial statements and quarterly performance metrics strongly indicates a periodic financial report. Since it covers a period shorter than a year (the first quarter), it fits the definition of an Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it contains comprehensive financial tables and detailed segment breakdowns, going beyond just key highlights. It is also not an Annual Report (10-K) as it is quarterly. Q1 2023
2023-05-03 English
Invitation to MorphoSys First Quarter 2023 Financial Results Conference Call on May 4, 2023
Earnings Release Classification · 1% confidence The document is an announcement titled "Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023". It explicitly states the date and time for publishing the Q1 2023 results and hosting a conference call/webcast to present those results. This is not the full financial report (IR or 10-K) itself, nor is it the initial release of the results (ER). Instead, it is an announcement inviting participants to an event where the results will be discussed. This fits the definition of an Earnings Release (ER) announcement, which typically precedes or coincides with the release of key highlights, or, more precisely, an announcement about an upcoming event related to earnings. Given the options, the content is directly related to the upcoming discussion of quarterly financial results. Since it is an invitation to the call where results are presented, it is most closely aligned with the Earnings Release (ER) category, which covers the initial announcement/event surrounding periodical financial results. Q1 2023
2023-04-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.